Browsing Tag
Kite Pharma
6 posts
Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition
Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma.
Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of…
Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused…
Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the…
Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO
US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its…
FDA grants approval to Yescarta for treatment of certain types of lymphoma
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from…